RxDoctor Payments Data

Dao Nguyen, MD

Internal Medicine · Westminster, CANPI 1811948680

Payments from drug & device makers

$1,621in general payments, 2019–2025

Across 25 payments — averaging $64.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$517
  • LEO Pharma Inc.$246
  • Novartis$244
  • Amgen$137
  • AbbVie$132
  • Bayer$114
  • plus $230 from 3 others

What the payments were for

  • Travel & lodging$211%
  • Food & beverage$1,60099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC9$517
LEO Pharma Inc.2$246
Novartis2$244
Amgen2$137
AbbVie2$132
Bayer5$114
Gilead1$110
Merck1$106
AstraZeneca1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,621 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$130,513
Medicare patients
228
Services billed
2,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin217$227,575
RybelsusSemaglutide90$139,636
JanuviaSitagliptin Phosphate78$91,647
FarxigaDapagliflozin Propanediol73$78,311
LinzessLinaclotide27$32,803
ProliaDenosumab15$25,331
KerendiaFinerenone25$19,576
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$16,299
VemlidyTenofovir Alafenamide11$15,789
TrulicityDulaglutide12$15,492
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$15,267
TradjentaLinagliptin14$11,195
Atorvastatin Calcium820$6,938
ShingrixVaricella-Zoster Ge/As01b/Pf25$5,125
Rosuvastatin Calcium202$4,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$106$91,64778 claims
AstraZenecaFarxiga$14$78,31173 claims
AbbVieLinzess$132$32,80327 claims
AmgenProlia$137$25,33115 claims
BayerKerendia$114$19,57625 claims
GileadVemlidy$110$15,78911 claims
Lilly USA, LLCTrulicity$517$15,49212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →